Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 19632318
Basu A, Sridharan S, Persaud S (2009) Regulation of protein kinase C delta downregulation by protein kinase C epsilon and mammalian target of rapamycin complex 2. Cell Signal 21, 1680-5 19632318
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

Y313-p - PKCD (human)
Modsite: ssEPVGIyQGFEKkT SwissProt Entrez-Gene
Orthologous residues
PKCD (human): Y313‑p, PKCD iso2 (human): Y313‑p, PKCD (mouse): Y311‑p, PKCD iso2 (mouse): Y311‑p, PKCD (rat): Y311‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  HeLa/CP (cisplatin resistant) cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester increase
Go_6983 phorbol_ester augment treatment-induced increase
rottlerin phorbol_ester augment treatment-induced increase
Go_6976 phorbol_ester augment treatment-induced increase
LY294002 phorbol_ester inhibit treatment-induced increase
rapamycin phorbol_ester inhibit treatment-induced increase
phorbol_ester PKCE (human) augment treatment-induced increase PKCE siRNA inhibits phorbol ester-induced increase
phorbol_ester RICTOR (human) augment treatment-induced increase Rictor siRNA inhibits phorbol ester-induced increase
phorbol_ester mTOR (human) augment treatment-induced increase mTOR siRNA inhibits phorbol ester-induced increase
phorbol_ester Abl (human) no effect upon treatment-induced increase Abl siRNA
phorbol_ester Src (human) no effect upon treatment-induced increase Src siRNA
phorbol_ester Fyn (human) no effect upon treatment-induced increase Fyn siRNA
phorbol_ester LYN (human) no effect upon treatment-induced increase Lyn siRNA
phorbol_ester Raptor (human) no effect upon treatment-induced increase raptor siRNA
phorbol_ester increase greater increase in cisplatin-resistant vs. wild-type HeLa cells

T507-p - PKCD (human)
Modsite: FGEsRAstFCGtPDy SwissProt Entrez-Gene
Orthologous residues
PKCD (human): T507‑p, PKCD iso2 (human): T538‑p, PKCD (mouse): T505‑p, PKCD iso2 (mouse): T531‑p, PKCD (rat): T505‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  HeLa/CP (cisplatin resistant) cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester increase
Go_6983 phorbol_ester inhibit treatment-induced increase
rottlerin phorbol_ester no effect upon treatment-induced increase
Go_6976 phorbol_ester no effect upon treatment-induced increase
LY294002 phorbol_ester no effect upon treatment-induced increase
rapamycin phorbol_ester no effect upon treatment-induced increase
phorbol_ester RICTOR (human) augment treatment-induced increase Rictor siRNA inhibits phorbol ester-induced increase
phorbol_ester mTOR (human) augment treatment-induced increase mTOR siRNA inhibits phorbol ester-induced increase
phorbol_ester PDK1 (human) no effect upon treatment-induced increase PDK1 siRNA
phorbol_ester Raptor (human) no effect upon treatment-induced increase raptor siRNA
phorbol_ester increase greater increase in cisplatin-resistant vs. wild-type HeLa cells

S645-p - PKCD (human)
Modsite: LNEkARLsysDKNLI SwissProt Entrez-Gene
Orthologous residues
PKCD (human): S645‑p, PKCD iso2 (human): S676‑p, PKCD (mouse): S643‑p, PKCD iso2 (mouse): S669‑p, PKCD (rat): S643‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  HeLa/CP (cisplatin resistant) cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester increase
Go_6983 phorbol_ester no effect upon treatment-induced increase
rottlerin phorbol_ester no effect upon treatment-induced increase
Go_6976 phorbol_ester no effect upon treatment-induced increase
LY294002 phorbol_ester inhibit treatment-induced increase
rapamycin phorbol_ester inhibit treatment-induced increase
phorbol_ester RICTOR (human) augment treatment-induced increase Rictor siRNA inhibits phorbol ester-induced increase
phorbol_ester mTOR (human) augment treatment-induced increase mTOR siRNA inhibits phorbol ester-induced increase
phorbol_ester PDK1 (human) no effect upon treatment-induced increase PDK1 siRNA
phorbol_ester Raptor (human) no effect upon treatment-induced increase raptor siRNA
phorbol_ester increase greater increase in cisplatin-resistant vs. wild-type HeLa cells

S664-p - PKCD (human)
Modsite: QsAFAGFsFVNPKFE SwissProt Entrez-Gene
Orthologous residues
PKCD (human): S664‑p, PKCD iso2 (human): S695‑p, PKCD (mouse): S662‑p, PKCD iso2 (mouse): S688‑p, PKCD (rat): S662‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  HeLa/CP (cisplatin resistant) cells
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester increase
LY294002 phorbol_ester inhibit treatment-induced increase
rapamycin phorbol_ester inhibit treatment-induced increase
phorbol_ester RICTOR (human) augment treatment-induced increase Rictor siRNA inhibits phorbol ester-induced increase
phorbol_ester mTOR (human) augment treatment-induced increase mTOR siRNA inhibits phorbol ester-induced increase
phorbol_ester Raptor (human) no effect upon treatment-induced increase raptor siRNA
phorbol_ester increase greater increase in cisplatin-resistant vs. wild-type HeLa cells